202 related articles for article (PubMed ID: 31197259)
21. Functional assessment of the mutational effects of human IRAK4 and MyD88 genes.
Yamamoto T; Tsutsumi N; Tochio H; Ohnishi H; Kubota K; Kato Z; Shirakawa M; Kondo N
Mol Immunol; 2014 Mar; 58(1):66-76. PubMed ID: 24316379
[TBL] [Abstract][Full Text] [Related]
22. Two human MYD88 variants, S34Y and R98C, interfere with MyD88-IRAK4-myddosome assembly.
George J; Motshwene PG; Wang H; Kubarenko AV; Rautanen A; Mills TC; Hill AV; Gay NJ; Weber AN
J Biol Chem; 2011 Jan; 286(2):1341-53. PubMed ID: 20966070
[TBL] [Abstract][Full Text] [Related]
23. A critical role for IRAK4 kinase activity in Toll-like receptor-mediated innate immunity.
Kim TW; Staschke K; Bulek K; Yao J; Peters K; Oh KH; Vandenburg Y; Xiao H; Qian W; Hamilton T; Min B; Sen G; Gilmour R; Li X
J Exp Med; 2007 May; 204(5):1025-36. PubMed ID: 17470642
[TBL] [Abstract][Full Text] [Related]
24. Clinical IRAK4 deficiency caused by homozygosity for the novel
Jia A; James E; Lu HY; Sharma M; Modi BP; Biggs CM; Hildebrand KJ; Chomyn A; Erdle S; Kular H; Turvey SE
Cold Spring Harb Mol Case Stud; 2020 Jun; 6(3):. PubMed ID: 32532880
[TBL] [Abstract][Full Text] [Related]
25. IRAK4 as a molecular target in the amelioration of innate immunity-related endotoxic shock and acute liver injury by chlorogenic acid.
Park SH; Baek SI; Yun J; Lee S; Yoon DY; Jung JK; Jung SH; Hwang BY; Hong JT; Han SB; Kim Y
J Immunol; 2015 Feb; 194(3):1122-30. PubMed ID: 25548221
[TBL] [Abstract][Full Text] [Related]
26. Effects of Toll-like receptor 7 and Toll-like receptor 9 signaling stimulators and inhibitors on chronic lymphocytic leukemia cells ex vivo and their interactions with cladribine.
Wolska A; Cebula-Obrzut B; Smolewski P; Robak T
Leuk Lymphoma; 2013 Jun; 54(6):1268-78. PubMed ID: 23078646
[TBL] [Abstract][Full Text] [Related]
27. Quercetin disrupts tyrosine-phosphorylated phosphatidylinositol 3-kinase and myeloid differentiation factor-88 association, and inhibits MAPK/AP-1 and IKK/NF-κB-induced inflammatory mediators production in RAW 264.7 cells.
Endale M; Park SC; Kim S; Kim SH; Yang Y; Cho JY; Rhee MH
Immunobiology; 2013 Dec; 218(12):1452-67. PubMed ID: 23735482
[TBL] [Abstract][Full Text] [Related]
28. IRAK4 turns IL-10+ phospho-FOXO+ monocytes into pro-inflammatory cells by suppression of protein kinase B.
Over B; Ziegler S; Foermer S; Weber AN; Bode KA; Heeg K; Bekeredjian-Ding I
Eur J Immunol; 2013 Jun; 43(6):1630-42. PubMed ID: 23519847
[TBL] [Abstract][Full Text] [Related]
29. Aberrant TIRAP and MyD88 expression in B-cell chronic lymphocytic leukemia.
Antosz H; Sajewicz J; Marzec-Kotarska B; Dmoszyńska A; Baszak J; Jargiełło-Baszak M
Blood Cells Mol Dis; 2013 Jun; 51(1):48-55. PubMed ID: 23419703
[TBL] [Abstract][Full Text] [Related]
30. Stimulation of iNOS expression and apoptosis resistance in B-cell chronic lymphocytic leukemia (B-CLL) cells through engagement of Toll-like receptor 7 (TLR-7) and NF-kappaB activation.
Hammadi A; Billard C; Faussat AM; Kolb JP
Nitric Oxide; 2008 Sep; 19(2):138-45. PubMed ID: 18474259
[TBL] [Abstract][Full Text] [Related]
31. Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering.
Tromp JM; Tonino SH; Elias JA; Jaspers A; Luijks DM; Kater AP; van Lier RA; van Oers MH; Eldering E
Oncogene; 2010 Sep; 29(36):5071-82. PubMed ID: 20581863
[TBL] [Abstract][Full Text] [Related]
32. TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target.
Kennedy E; Coulter E; Halliwell E; Profitos-Peleja N; Walsby E; Clark B; Phillips EH; Burley TA; Mitchell S; Devereux S; Fegan CD; Jones CI; Johnston R; Chevassut T; Schulz R; Seiffert M; Agathanggelou A; Oldreive C; Davies N; Stankovic T; Liloglou T; Pepper C; Pepper AGS
Blood; 2021 Jun; 137(22):3064-3078. PubMed ID: 33512408
[TBL] [Abstract][Full Text] [Related]
33. Deficiency in IRAK4 activity attenuates manifestations of murine Lupus.
Murphy M; Pattabiraman G; Manavalan TT; Medvedev AE
Eur J Immunol; 2017 May; 47(5):880-891. PubMed ID: 28295231
[TBL] [Abstract][Full Text] [Related]
34. The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model.
Blunt MD; Carter MJ; Larrayoz M; Smith LD; Aguilar-Hernandez M; Cox KL; Tipton T; Reynolds M; Murphy S; Lemm E; Dias S; Duncombe A; Strefford JC; Johnson PW; Forconi F; Stevenson FK; Packham G; Cragg MS; Steele AJ
Blood; 2015 Jun; 125(26):4032-41. PubMed ID: 25957390
[TBL] [Abstract][Full Text] [Related]
35. Postoperative ileus involves interleukin-1 receptor signaling in enteric glia.
Stoffels B; Hupa KJ; Snoek SA; van Bree S; Stein K; Schwandt T; Vilz TO; Lysson M; Veer CV; Kummer MP; Hornung V; Kalff JC; de Jonge WJ; Wehner S
Gastroenterology; 2014 Jan; 146(1):176-87.e1. PubMed ID: 24067878
[TBL] [Abstract][Full Text] [Related]
36. Regulator of calcineurin 1 differentially regulates TLR-dependent MyD88 and TRIF signaling pathways.
Pang Z; Junkins RD; Raudonis R; MacNeil AJ; McCormick C; Cheng Z; Lin TJ
PLoS One; 2018; 13(5):e0197491. PubMed ID: 29799862
[TBL] [Abstract][Full Text] [Related]
37. Heterogeneous functional effects of concomitant B cell receptor and TLR stimulation in chronic lymphocytic leukemia with mutated versus unmutated Ig genes.
Chatzouli M; Ntoufa S; Papakonstantinou N; Chartomatsidou E; Anagnostopoulos A; Kollia P; Ghia P; Muzio M; Stamatopoulos K; Belessi C
J Immunol; 2014 May; 192(10):4518-24. PubMed ID: 24719462
[TBL] [Abstract][Full Text] [Related]
38. Targeting inflammatory pathways in chronic lymphocytic leukemia.
Rozovski U; Keating MJ; Estrov Z
Crit Rev Oncol Hematol; 2013 Dec; 88(3):655-66. PubMed ID: 23941728
[TBL] [Abstract][Full Text] [Related]
39. Beneficial effect of low-level laser therapy in acute lung injury after i-I/R is dependent on the secretion of IL-10 and independent of the TLR/MyD88 signaling.
Carvalho JL; Britto A; de Oliveira AP; Castro-Faria-Neto H; Albertini R; Anatriello E; Aimbire F
Lasers Med Sci; 2017 Feb; 32(2):305-315. PubMed ID: 27924419
[TBL] [Abstract][Full Text] [Related]
40. Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4.
Tumey LN; Boschelli DH; Bhagirath N; Shim J; Murphy EA; Goodwin D; Bennett EM; Wang M; Lin LL; Press B; Shen M; Frisbie RK; Morgan P; Mohan S; Shin J; Rao VR
Bioorg Med Chem Lett; 2014 May; 24(9):2066-72. PubMed ID: 24726805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
